source
- Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancerHS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…
- Phase 3 STRIKE trial to assess disease-free survival of adjuvant tivozanib plus pembrolizumab in high-risk RCCDr. Bradley McGregor, director of clinical research at the Lank Center of Genitourinary Oncology, outlined the key objectives of the ongoing phase 3 STRIKE trial (NCT06661720). The study evaluates…